Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases

被引:23
|
作者
Hashimoto, Kosuke [1 ]
Rogozin, Igor B. [1 ]
Panchenko, Anna R. [1 ]
机构
[1] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA
基金
日本学术振兴会; 美国国家卫生研究院;
关键词
cancer mutation; receptor tyrosine kinase; protein structure; kinase activation; mutation spectra; double mutations; GROWTH-FACTOR RECEPTOR; LUNG-CANCER; MULTIPLE MUTATIONS; MISSENSE MUTATIONS; DNA-POLYMERASE; EGFR MUTANTS; TRANSIENT HYPERMUTABILITY; CHRONOCOORDINATE EVENTS; INHIBITOR SENSITIVITY; PROTEIN INTERACTIONS;
D O I
10.1002/humu.22145
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aberrant activation of receptor tyrosine kinases (RTKs) is a common feature of many cancer cells. It was previously suggested that the mechanisms of kinase activation in cancer might be linked to transitions between active and inactive states. Here, we estimate the effects of single and double cancer mutations on the stability of active and inactive states of the kinase domains from different RTKs. We show that singleton cancer mutations destabilize active and inactive states; however, inactive states are destabilized more than the active ones, leading to kinase activation. We show that there exists a relationship between the estimate of oncogenic potential of cancer mutation and kinase activation. Namely, more frequent mutations have a higher activating effect, which might allow us to predict the activating effect of the mutations from the mutation spectra. Independent evolutionary analysis of mutation spectra complements this observation and finds the same frequency threshold defining mutation hotspots. We analyze double mutations and report a positive epistasis and additional advantage of doublets with respect to cancer cell fitness. The activation mechanisms of double mutations differ from those of single mutations and double mutation spectrum is found to be dissimilar to the mutation spectrum of singletons. Hum Mutat 33:15661575, 2012. Published 2012 Wiley Periodicals, Inc.*
引用
收藏
页码:1566 / 1575
页数:10
相关论文
共 9 条
  • [1] Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
    Saraon, Punit
    Pathmanathan, Shivanthy
    Snider, Jamie
    Lyakisheva, Anna
    Wong, Victoria
    Stagljar, Igor
    ONCOGENE, 2021, 40 (24) : 4079 - 4093
  • [2] Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations
    Dhakar, Ramgopal
    Dakal, Tikam Chand
    Sharma, Amit
    GENOMICS, 2022, 114 (04)
  • [3] Review Article Receptor tyrosine kinases in breast cancer treatment: unraveling the potential
    Qi, Yu
    Deng, Shu-Min
    Wang, Kuan-Song
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (09): : 4172 - 4196
  • [4] Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
    Duplaquet, Leslie
    Figeac, Martin
    Lepretre, Frederic
    Frandemiche, Charline
    Villenet, Celine
    Sebda, Sheherazade
    Sarafan-Vasseur, Nasrin
    Benozene, Melanie
    Vinchent, Audrey
    Goormachtigh, Gautier
    Wicquart, Laurence
    Rousseau, Nathalie
    Beaussire, Ludivine
    Truant, Stephanie
    Michel, Pierre
    Sabourin, Jean-Christophe
    Galateau-Salle, Francoise
    Copin, Marie-Christine
    Zalcman, Gerard
    De Launoit, Yvan
    Fafeur, Veronique
    Tulasne, David
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (06) : 1137 - 1148
  • [5] Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
    Wang, Ming-Hai
    Padhye, Snehal S.
    Guin, Sunny
    Ma, Qi
    Zhou, Yong-qing
    ACTA PHARMACOLOGICA SINICA, 2010, 31 (09) : 1181 - 1188
  • [6] Mass Spectrometry Mapping of Epidermal Growth Factor Receptor Phosphorylation Related to Oncogenic Mutations and Tyrosine Kinase Inhibitor Sensitivity
    Zhang, Guolin
    Fang, Bin
    Liu, Richard Z.
    Lin, Huiyi
    Kinose, Fumi
    Bai, Yun
    Oguz, Umut
    Remily-Wood, Elizabeth R.
    Li, Jiannong
    Altiok, Soner
    Eschrich, Steven
    Koomen, John
    Haura, Eric B.
    JOURNAL OF PROTEOME RESEARCH, 2011, 10 (01) : 305 - 319
  • [7] Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
    Ming-Hai Wang
    Snehal S Padhye
    Sunny Guin
    Qi Ma
    Yong-qing Zhou
    Acta Pharmacologica Sinica, 2010, 31 : 1181 - 1188
  • [8] Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies
    Wei, Ying
    Erfani, Sonia
    Schweer, David
    de Gouvea, Rafael
    Qadir, Javeria
    Shi, Junfeng
    Cheng, Kai
    Wu, Dabao
    Craven, Rolf
    Wu, Yadi
    Olivier, Thibault
    Baldwin, Lauren A.
    Zhou, Binhua
    Zhou, Ying
    Zhao, Weidong
    Yang, Burton B.
    Ueland, Frederick R.
    Yang, Xiuwei H.
    MOLECULAR THERAPY ONCOLYTICS, 2023, 28 : 293 - 306
  • [9] Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors
    Wei, Zhigang
    An, Tongtong
    Wang, Zhijie
    Chen, Keneng
    Bai, Hua
    Zhu, Guangying
    Duan, Jianchun
    Wu, Meina
    Yang, Lu
    Zhuo, Minglei
    Wang, Yuyan
    Liu, Xuyi
    Wang, Jie
    THORACIC CANCER, 2014, 5 (02) : 126 - 132